MultiOmic Health, a London, UK-based artificial intelligence (AI)-enabled drug discovery company, raised $6.2M in funding.
The round was led by Hoxton Ventures, with participation from Ada Ventures, MMC Ventures and Verve Ventures.
The company intends to use the funds to demonstrate proof-of-concept for its MOHSAIC platform in diabetic kidney disease.
Led by Robert Thong, Chief Executive Officer, and Alasdair Thong, Co-Founder and Non-Executive Director, MultiOmic Health is an AI-enabled drug discovery (AIDD) start-up focused on metabolic syndrome-related diseases. It partners with healthcare providers to source and analyse de-identified patient data and bio-samples. Its MOHSAIC platform combines integrated multi-omics analysis and computational systems biology modelling with targeted wet laboratory experiments to originate novel precision therapeutic concepts that MultiOmic commercialises via partnerships with established biopharma companies.
Since beginning operations in May 2021, the company has raised a total of US$8.6M, including an earlier round led by San Francisco-based Fifty Years.
FinSMEs
04/05/2023